Solta Medical Provides Update on Liposonix Launch
HAYWARD, Calif., March 7, 2012 /PRNewswire/ -- Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today provided an update on the launch of the second generation Liposonix non-invasive fat reduction system recently approved by the FDA.
A majority of the Company's approximately twenty key opinion leaders (KOLs), comprised of leading plastic surgeons and dermatologists, who received Liposonix systems in mid-December as part of the pre-launch trial, have successfully evaluated and purchased the product. The company expects that virtually all the remaining KOL's evaluating the system will purchase the device this month. Liposonix was officially introduced in early January of 2012.
"For the full year 2012, we provided guidance that we would generate approximately $17 million in Liposonix revenue," said Stephen J. Fanning, Chairman, President and CEO of Solta Medical. "Through the first two months of the year, we are on track to meet or exceed this guidance. Systems have been sold, on average, at list price."
The Liposonix system uses non-invasive, high-intensity focused ultrasound (or HIFU) to permanently get rid of targeted fat around the waistline, love handles and abdomen, without surgery. The average waistline reduction after just one, 1-hour treatment is about one inch – which typically means one dress or pant size. Results are usually seen in 8 to 12 weeks (which is the time needed for the body to naturally remove the treated fat).
Since its introduction, Liposonix has been featured in many high profile media outlets, including national broadcast programs such as Dr. Oz, The Doctors, and 20/20 with Barbara Walters. Thus far the Liposonix treatment has received very positive reviews from patients as reflected in on-line aesthetic procedure forums.
"The Gen 2 system is proving to provide several distinct advantages compared with the first generation, including a larger treatment tip, which enables clinicians to deliver comparable energy over multiple passes while maintaining a treatment time of about an hour," continued Mr. Fanning. "This has improved the treatment experience for both patients and physicians."
"In addition, most physicians using Liposonix do not find it necessary to medicate patients for the treatment, and those that do, are using non-narcotic medication, resulting in little to no post-treatment downtime. The acceptance and feedback from physicians about our Gen 2 system has been extremely positive and Liposonix is delivering on its promise of one treatment, one hour, one inch or pant size smaller," Mr. Fanning concluded.
The Company will be exhibiting Liposonix along with all of its industry leading aesthetic solutions at the American Academy of Dermatology meeting from March 17 to 19 at the San Diego Convention Center (Booth #1211).
About Solta Medical, Inc.
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry´s six premier brands: Thermage®, Fraxel®, Liposonix®, Isolaz®, CLARO® and Clear + Brilliant®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. The Liposonix system uses advanced high–intensity focused ultrasound (HIFU) technology to permanently destroy targeted fat just beneath the skin in the treatment areas of the abdomen and flanks as a noninvasive, nonsurgical approach to aesthetic waist circumference reduction. Isolaz was the first laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild–to–moderate inflammatory acne. CLARO is a personal care acne system that is the first FDA cleared over–the–counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. Clear + Brilliant is a unique, cost–effective treatment that utilizes safe, fractional laser technology to correct and prevent early signs of aging and is FDA cleared and CE marked. Since 2002, over one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding expected future purchases of Liposonix systems and anticipated revenue. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Factors that might cause such a difference include the risk that physician adoption of our systems does not grow, the risk that customers do not continue to purchase treatment tips, the possibility that the market for the sale of new products does not develop as expected, and the risks relating to Solta Medical's ability to achieve its stated financial goals as a result of, among other things, economic conditions and consumer and physician confidence causing changes in consumer and physician spending habits that affect demand for our products and treatments. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-Q for the quarter ended September 30, 2011, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
SOURCE Solta Medical, Inc.